论文部分内容阅读
采用体外培养的MC技术和血清药理学方法,分为治糖保肾颗粒组、贝那普利组、模型组,并设高、中、低三种剂量。用酶联免疫吸附测定法(ELISA)测定细胞上清液中FN的含量,放射免疫测定法(RIA)测定细胞上清液中LN、CL-Ⅳ的含量。结果高糖能明显刺激MC增殖,同时促进FN、LN和CL-Ⅳ分泌。而治糖保肾颗粒能抑制MC增殖,抑制MC分泌FN、LN和CL-Ⅳ,并呈一定量效关系。贝那普利也有相似的作用。结论肾小球系膜细胞是治糖保肾颗粒发挥治疗作用的重要靶细胞,抑制细胞外基质聚积可能是该方延缓糖尿病肾病发展的机制之一。
Using in vitro cultured MC technology and serum pharmacology, divided into Zhitangbaoshen granule group, benazepril group and model group, and set high, medium and low doses. The content of FN in the cell supernatant was determined by enzyme-linked immunosorbent assay (ELISA), and the content of LN, CL-IV in the cell supernatant was determined by radioimmunoassay (RIA). Results High glucose stimulated the proliferation of MC and promoted the secretion of FN, LN and CL-IV. The treatment of sugar Baoshen Granules can inhibit MC proliferation, inhibition of MC secretion of FN, LN and CL-IV, and a certain dose-effect relationship. Benazepril also has a similar effect. Conclusion Glomerular mesangial cells are important target cells for Zhiganbaoshen granules to play a therapeutic role. Inhibition of extracellular matrix accumulation may be one of the mechanisms by which this side delays the development of diabetic nephropathy.